Premium
Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
Author(s) -
Liu ChenHua,
Liu ChunJen,
Su TungHung,
Yang HungChih,
Hong ChunMing,
Tseng TaiChung,
Chen PeiJer,
Chen DingShinn,
Kao JiaHorng
Publication year - 2018
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13912
Subject(s) - ombitasvir , paritaprevir , dasabuvir , medicine , ritonavir , ribavirin , gastroenterology , hepatitis c , viral load , adverse effect , hepatitis c virus , virology , virus , antiretroviral therapy
Background and Aim The real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) remain limited for East Asian hepatitis C virus genotype 1b (HCV‐1b) patients. The study aimed to evaluate the antiviral responses of PrOD‐based regimens for HCV‐1b patients in Taiwan. Methods The study performed a retrospective analysis of 103 HCV‐1b patients receiving PrOD with or without ribavirin (RBV) for 12 weeks. Data were analyzed to assess the on‐treatment and off‐therapy HCV viral load and on‐treatment adverse events. The pre‐specified characteristics related to sustained virologic response 12 weeks off therapy (SVR 12 ) were compared. Results At treatment week 4, 100 of 102 patients (98.0%) had serum HCV RNA level < 25 IU/mL. The SVR 12 was achieved in 101 of 103 patients (98.1%, [95% confidence interval: 93.2–99.5%]). All except one (99.0%) patients tolerated treatment well without treatment interruption. One cirrhotic patient discontinued treatment at week 1 due to hepatic decompensation. Twenty‐four patients (23.3%) had ≥ grade 2 elevation in total bilirubin levels, and 21 of them (87.5%) had indirect type hyperbilirubinemia. The stratified SVR 12 rates were comparable in terms of sex, age, body mass index, prior treatment experience, hepatitis B virus surface antigen status, RBV usage, baseline and week 2 viral load, renal function, and hepatic fibrosis stage. Conclusions Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without RBV are efficacious and generally well tolerated for treatment of HCV‐1b patients in Taiwan.